Nautilus Biotechnolgy (NAUT)

• Market cap: $221M
• 1 day: -2.22%
• 5 days: -9.74%
• 1 month: -24.79%
• 3 months: -42.86%
• 6 months: -30.43%
• Year to date: -41.72%
• 1 year: -41.33%
• 5 years: -84.00%
• 10 years: -84.00%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Employees: 161

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 3

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

22% more capital invested

Capital invested by funds: $151M [Q2] → $183M (+$32.4M) [Q3]

8% more funds holding

Funds holding: 77 [Q2] → 83 (+6) [Q3]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]

0.16% less ownership

Funds ownership: 51.35% [Q2] → 51.18% (-0.16%) [Q3]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $1.75 1% downside
• Avg. target: $1.75 1% downside
• High target: $1.75 1% downside

1 analyst rating

• positive: 0 0%
• neutral: 0 0%
• negative: 1 100%

Goldman Sachs Matthew Sykes 64% 1-year accuracy 29 / 45 met price target

1% downside $1.75

Sell Downgraded

5 Dec 2024